Filgrastim Market Report 2024 (Global Edition)

Global Filgrastim Market Report 2024 Market Size Split by By Drug Type (Biologic, Biosimilar), by By Distribution Channel: (Hospital pharmacies, Retail pharmacies, Online pharmacies), by By Indication...

Filgrastim Market Report Description

We have various report editions of Filgrastim Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Filgrastim Market Insights Video

Competitive Landscape of the Filgrastim market

In the competitive landscape of pharmaceuticals, Abbott Laboratories, Amgen, Apotex, Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Kirin Holding (Kyowa Kirin), Novartis, Pfizer, Teva Pharmaceutical Industries Ltd., and Toksöz Group stand as major players. Each company brings unique strengths in research, development, and manufacturing to the global market. They compete fiercely to introduce innovative drugs, expand market reach, and navigate regulatory challenges. Market dynamics, patent expirations, and emerging technologies constantly reshape this landscape, influencing companies' strategies and market positioning. Amidst this competition, maintaining a balance between innovation, cost-effectiveness, and regulatory compliance is crucial for sustained success.

In July 1, 2017, or as contracts permit, INEOS Calabrian will increase pricing for Sodium Metabisulfite by $0.03 per pound. This increase is due to a significant increase in market demand.

(Source:https://www.ineos.com/businesses/ineos-enterprises/businesses/ineos-calabrian/news/ineos-calabrian-increases-pricing-for-its-sodium-metabisulfite/)

Top Companies Market Share in Filgrastim Industry: (In no particular order of Rank)

• Abbott Laboratories
• Amgen
• Apotex
• Cadila Pharmaceuticals
• Dr. Reddy's Laboratories
• Kirin Holding (Kyowa Kirin)
• Novartis
• Pfizer
• Teva Pharmaceutical Industries Ltd.
• Toksöz Group
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Filgrastim market

Which Region Dominates the Filgrastim market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. The dominance of the North America region in the filgrastim market is primarily driven by several factors. North America boasts advanced healthcare infrastructure and a well-established pharmaceutical industry, facilitating widespread availability and distribution of filgrastim products. the presence of key market players headquartered in North America contributes significantly to its dominance in the filgrastim market. These companies have robust research and development capabilities, allowing for continuous innovation and the introduction of new filgrastim formulations and delivery methods.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is witnessing an unprecedented surge in economic growth, expanding at the fastest Compound Annual Growth Rate (CAGR) compared to other global regions. This remarkable growth can be attributed to several factors, including rapid industrialization, technological advancements, favorable government policies, and a burgeoning consumer market. Countries like China, India, and Southeast Asian nations have emerged as key drivers of this growth, attracting significant investments from both domestic and international sources. The Asia Pacific region's dynamic demographic landscape, characterized by a large and increasingly affluent middle class, presents lucrative opportunities for businesses across various sectors. Rising disposable incomes, urbanization, and shifting consumer preferences towards convenience and quality products/services are driving demand and innovation in industries such as retail, e-commerce, healthcare, and technology. As the region continues to embrace globalization and digitalization, it is poised to maintain its position as a powerhouse of economic growth, offering immense potential for businesses seeking to capitalize on its vibrant and dynamic market dynamics.

 

The current report Scope analyzes Filgrastim Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Filgrastim Market

According to Cognitive Market Research, the global filgrastim market size was estimated at USD 565.2 Million out of which North America held the market of more than 40% of the global revenue with a market size of USD 226.8 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.1% from 2024 to 2031. This growth is propelled by factors such as increasing incidences of neutropenia-related conditions and the rising adoption of biologic and biosimilar drugs. The increasing prevalence of cancer and other hematological disorders requiring chemotherapy remains a significant contributor to market expansion. As the population ages and healthcare infrastructure improves, the demand for filgrastim in treating chemotherapy-induced neutropenia rises correspondingly. The region's strong focus on biotechnology and pharmaceutical research and development ensures the availability of advanced treatments, including biosimilar filgrastim options, fostering competition and driving market growth. This competitive landscape encourages innovation and cost-effective solutions, benefiting both healthcare providers and patients. The North American filgrastim market shows significant promise, driven by factors such as increasing healthcare expenditure and the growing prevalence of neutropenia-related conditions. With the dominance of the USA and notable contributions from Canada and Mexico, the region presents lucrative opportunities for market players.

• According to Cognitive Market Research, the US had a major share in the filgrastim market with a market size of USD 178.38 million in 2024 and is projected to grow at a CAGR of 0.9% during the forecast period. The USA leads the North American filgrastim market due to its large population, advanced healthcare infrastructure, and high healthcare expenditure, providing ample opportunities for market penetration and growth.
• The Canada filgrastim market had a market share of USD 27.13 million in 2024 and is projected to grow at a CAGR of 1.9% during the forecast period. Canada emerges as the fastest-growing country in the North American filgrastim market, fueled by factors such as increasing awareness of neutropenia-related conditions and the growing demand for biologic and biosimilar drugs within its healthcare system.
• The Mexico filgrastim market is projected to witness growth at a CAGR of 1.6% during the forecast period with a market size of USD 20.57 million in 2024.

Europe Filgrastim Market

According to Cognitive Market Research, the global filgrastim market size was estimated at USD 565.2 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 169.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.4% from 2024 to 2031. In Europe, the market for filgrastim is witnessing steady growth driven by several factors. The increasing prevalence of cancer and other conditions requiring chemotherapy has heightened the demand for filgrastim, particularly in treating chemotherapy-induced neutropenia. The rise in the aging population across Europe contributes to the prevalence of chronic neutropenia, further boosting the market. The introduction of biosimilar filgrastim has also played a significant role in market expansion by offering cost-effective alternatives to the original biologic drug, thus improving accessibility and affordability for patients and healthcare systems. the presence of well-established healthcare infrastructure and reimbursement policies in European countries supports the adoption of filgrastim across various distribution channels, including hospital, retail, and online pharmacies. These channels provide convenient access to patients, contributing to market growth. Furthermore, ongoing research and development activities focusing on improving the efficacy and safety profiles of filgrastim variants continue to drive innovation in the region. In conclusion, the European filgrastim market exhibits promising growth prospects fueled by increasing demand for biologics and biosimilars. With a strategic focus on research and development and favorable government policies, the region is poised for sustained expansion in the coming years.

• The United Kingdom filgrastim market had a market share of USD 28.49 million in 2024 and is projected to grow at a CAGR of 2.2% during the forecast period.
• The France filgrastim market is projected to witness growth at a CAGR of 0.6% during the forecast period with a market size of USD 22.21 million in 2024.
• According to Cognitive Market Research, the Germany Filgrastim market size was valued at USD 33.57 million in 2024 and is projected to grow at a CAGR of 1.6% during the forecast period. Germany leads as the dominant country in the European filgrastim market due to its robust healthcare infrastructure and high demand for advanced pharmaceuticals, particularly biosimilars.
• The Italy filgrastim market is projected to witness growth at a CAGR of 0.8% during the forecast period with a market size of USD 14.58 million in 2024.
• The Russia Filgrastim market is projected to witness growth at a CAGR of 0.4% during the forecast period with a market size of USD 26.28 million in 2024. Russia emerges as the fastest-growing country in the European filgrastim market, driven by improving healthcare infrastructure, rising healthcare spending, and increasing awareness about the benefits of biologic and biosimilar drugs.
• The Spain filgrastim market is projected to witness growth at a CAGR of 0.5% during the forecast period with a market size of USD 13.90 million in 2024.
• The Luxembourg filgrastim market is projected to witness growth at a CAGR of 1.5% during the forecast period with a market size of USD 5.26 million in 2024.
• The Portugal filgrastim market is projected to witness growth at a CAGR of 1.2% during the forecast period with a market size of USD 3.56 million in 2024.
• The Greece filgrastim market is projected to witness growth at a CAGR of 1.7% during the forecast period with a market size of USD 2.03 million in 2024.
• Rest of Europe filgrastim market is projected to witness growth at a CAGR of 0.1% during the forecast period with a market size of USD 26.28 million in 2024.

Asia Pacific Filgrastim Market

According to Cognitive Market Research, the global filgrastim market size was estimated at USD 565.2 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 130.0 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031. In the Asia Pacific region, The Asia Pacific region has witnessed significant growth in the market for filgrastim, driven by several factors. Increased prevalence of cancer, particularly in countries with burgeoning populations like China and India, has heightened the demand for filgrastim, especially in the treatment of chemotherapy-induced neutropenia. Improving healthcare infrastructure and rising awareness about the benefits of advanced medical treatments have led to greater adoption of filgrastim across the region. The introduction of biosimilar filgrastim has further fueled market growth by offering more affordable treatment options, particularly in emerging economies where healthcare expenditure can be a significant concern. Government initiatives aimed at improving cancer care and access to essential medications have also played a crucial role in driving market expansion. As the Asia Pacific region continues to witness economic development and investments in healthcare, the market for filgrastim is expected to experience sustained growth, addressing the increasing demand for supportive care in cancer treatment and other indications.

• According to Cognitive Market Research, the China filgrastim market size was valued at USD 58.50 million in 2024 and is projected to grow at a CAGR of 4.4% during the forecast period. China emerging as the dominant player due to its large population and increasing healthcare investments.
• The Japan filgrastim market is projected to witness growth at a CAGR of 3.4% during the forecast period with a market size of USD 17.94 million in 2024.
• The India filgrastim market had a market share of USD 15.60 million in 2024 and is projected to grow at a CAGR of 6.7% durig the forecast period stands out as the fastest-growing market, propelled by rising cancer prevalence and expanding biosimilar adoption.
• The South Korea filgrastim market is projected to witness growth at a CAGR of 4.0% during the forecast period with a market size of USD 13.0 million in 2024.
• The Australia filgrastim market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 6.76 million in 2024.
• The South East Asia filgrastim market is projected to witness growth at a CAGR of 5.9% during the forecast period with a market size of USD 8.97 million in 2024.
• The Rest of Asia Pacific filgrastim market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD 9.23 million in 2024.

South America Filgrastim Market

According to Cognitive Market Research, the global filgrastim market size was estimated at USD 565.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 28.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.4% from 2024 to 2031. Latin America's pharmaceutical market is witnessing significant growth, driven by factors such as increasing healthcare expenditure, expanding access to healthcare services, and a growing aging population. Within this landscape, the market for filgrastim, a vital medication for managing neutropenia, is also experiencing expansion. Latin America's evolving healthcare infrastructure, including the expansion of hospital and retail pharmacy networks, enhances accessibility to filgrastim across various distribution channels. The emergence of biosimilar filgrastim offers cost-effective alternatives, facilitating broader patient access.Latin America's filgrastim market shows promise with steady growth, driven by factors like increasing cancer prevalence and improving healthcare infrastructure. Government initiatives to enhance healthcare access further contribute to market expansion, indicating a positive outlook for the region's pharmaceutical sector.

• According to Cognitive Market Research, the Brazil filgrastim market size was valued at USD 12.10 million in 2024 and is projected to grow at a CAGR of 2.9% during the forecast period. driven by its robust food and beverage industry and growing industrial sectors.
• The Argentina filgrastim market had a market share of USD 4.75 million in 2024 and is projected to grow at a CAGR of 3.2% during the forecast period. The demand is augmented by Argentina's increasing food and beverages industry.
• The Colombia filgrastim market is projected to witness growth at a CAGR of 2.1% during the forecast period with a market size of USD 2.52 million in 2024.
• The Peru filgrastim market is projected to witness growth at a CAGR of 2.5% during the forecast period with a market size of USD 2.32 million in 2024.
• The Chile filgrastim market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 2.90 million in 2024.
• The Rest of Latin America Filgrastim market is projected to witness growth at a CAGR of 1.4% during the forecast period with a market size of USD 4.55 million in 2024.

Middle East and Africa Filgrastim Market

According to Cognitive Market Research, the global filgrastim market size was estimated at USD 565.2 Million out of which Middle East and Africa held the major market of around 2.6% of the global revenue with a market size of USD 11.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.6% from 2024 to 2031. In the Middle East and Africa (MEA) region, the pharmaceutical market is experiencing notable growth driven by several factors. One significant contributor is the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer, which is boosting demand for various medications including filgrastim. Governments in the region are investing in healthcare infrastructure and implementing healthcare reforms to improve access to healthcare services, thereby expanding the patient pool for pharmaceutical products. The rising healthcare expenditure and growing awareness about the importance of preventive healthcare are further fueling market growth. Moreover, the introduction of biosimilar filgrastim is enhancing affordability and accessibility, particularly in countries where healthcare resources are limited. Despite these opportunities, challenges such as regulatory complexities and pricing pressures persist in the MEA pharmaceutical market.

• The GCC Countries filgrastim market is projected to witness growth at a CAGR of 3.4% during the forecast period with a market size of USD 4.84 million in 2024. The growth of the filgrastim market in GCC countries is driven by increasing healthcare expenditure and a rising prevalence of chronic diseases necessitating supportive care treatments.
• The Egypt filgrastim market is projected to witness growth at a CAGR of 2.9% during the forecast period with a market size of USD 1.19 million in 2024.
• The South Africa Filgrastim market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD 1.79 million in 2024. Driven by expanding food processing and water treatment industries, coupled with government initiatives to modernize industrial sectors and improve water quality.
• The Turkey filgrastim market is projected to witness growth at a CAGR of 2.1% during the forecast period with a market size of USD 0.97 million in 2024.
• The Nigeria filgrastim market is projected to witness growth at a CAGR of 1.7% during the forecast period with a market size of USD 1.19 million in 2024.
• The Rest of MEA filgrastim market is projected to witness growth at a CAGR of 1.6% during the forecast period with a market size of USD 1.33 million in 2024.

Filgrastim Market Analysis

Filgrastim Market Technology Segment Analysis

According to Cognitive Market Research, the largest segment in the Filgrastim market is typically the Food Grade category. By drug type, the largest segment typically consists of small molecule drugs. These drugs are chemically synthesized and make up a significant portion of pharmaceuticals on the market due to their versatility and relatively low production costs. Small molecule drugs are often used to treat a wide range of conditions, from common ailments to chronic diseases, making them a staple in healthcare.

The fastest-growing segment tends to be biologics. Biologic drugs are derived from living organisms and are often more complex in structure compared to small molecule drugs. They are used to treat conditions such as cancer, autoimmune diseases, and genetic disorders. Biosimilars, which are highly similar versions of approved biologics, also contribute to this segment's growth due to their potential cost-saving benefits and increasing market acceptance. The complexity of biologics and their production processes can make them more expensive but also offers greater specificity and efficacy in treating certain diseases.

• Biologic
• Biosimilar

 

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Filgrastim Industry. Request a Free Sample PDF!

Filgrastim Market Dimensions Segment Analysis

According to Cognitive Market Research, Hospital pharmacies constitute one of the largest segments in the pharmaceutical distribution channel. They cater primarily to inpatient and outpatient services within healthcare institutions. With direct access to patients, hospitals often command a significant portion of pharmaceutical sales, especially for specialized medications and treatments

Online pharmacies represent the fastest-growing segment in the distribution channel. With the rise of e-commerce and digital health services, online pharmacies offer convenience, competitive pricing, and accessibility to a broad customer base. The ease of ordering prescriptions and over-the-counter medications from the comfort of one's home has fueled the rapid expansion of online pharmacy services. Additionally, advancements in telemedicine have further accelerated the growth of online pharmacies, making healthcare more accessible to remote and underserved populations

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Filgrastim By Indication Segment Analysis

According to Cognitive Market Research, the food and beverage industry stands out as the segments related to neutropenia, chemotherapy-induced neutropenia stands as the largest and fastest-growing. It pertains to a significant portion of neutropenia cases, affecting cancer patients undergoing chemotherapy. Chemotherapy drugs often suppress bone marrow function, leading to a decrease in neutrophil production and increasing the risk of infections. As cancer treatments advance and more patients undergo chemotherapy, the incidence of CIN rises. Moreover, heightened awareness and proactive management of CIN contribute to its substantial growth within the neutropenia segment. Efforts to mitigate its impact through supportive care and emerging treatments further underscore its prominence in the medical landscape.

• Chemotherapy-induced Neutropenia
• Chronic Neutropenia

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion